What Treovir does

Treovir is a clinical-stage biopharmaceutical company founded in 2019 to develop and commercialize G207, a modified oncolytic herpes simplex virus type 1 (HSV-1) immunotherapy, for pediatric brain tumors. The company targets children with recurrent high-grade glioma (HGG) — including glioblastoma and medulloblastoma — an addressable population of approximately 3,900 children diagnosed with primary brain tumors each year in the US, an indication with zero FDA-approved therapies. The firm is headquartered in Bala Cynwyd, Pennsylvania, operates with 1-10 employees, and is privately held with no disclosed institutional venture capital backing.

G207 is engineered to selectively infect and kill tumor cells while sparing healthy tissue and is administered as a single intratumoral infusion. The mechanism combines direct oncolysis with a T-cell-mediated inflammatory response that converts immunologically "cold" tumors into "hot" ones, recruiting the patient's own immune system to attack residual disease. Treovir has dosed more than 40 adult and nearly 20 pediatric brain tumor patients across three Phase 1 trials, with Phase 1 pediatric data published in the New England Journal of Medicine (April 2021) showing overall survival of 12.2 months versus 5.6 months for historical controls and no serious adverse events. A Phase 2 study in 30 pediatric patients with recurrent HGG was launched in 2024 at MD Anderson Cancer Center and Memorial Sloan Kettering to support registration, alongside a Phase 1 combination study with radiation in cerebellar tumors.

Treovir is pre-revenue. The economic model is contingent on FDA and EMA approval of G207, at which point revenue would be generated through commercial sales of the therapy administered in hospital/clinical settings. G207 has received FDA Fast Track designation, FDA Orphan Product designation for glioma, medulloblastoma, and pediatric neuroectodermal tumors (PNET), and EMA Orphan designation for glioma. The company operates an Expanded Access Program for patients outside clinical trials and runs trials in partnership with MD Anderson, Memorial Sloan Kettering, Children's of Alabama, St. Louis Children's Hospital, the Pediatric Brain Tumor Consortium, NIH, and UAB Medicine, where scientific co-founder G. Yancey Gillespie (CSO) is Professor Emeritus of Neurosurgery and where James Markert chairs Neurosurgery.

Name

Treovir

Legal name

Treovir LLC

Website

https://treovir.com

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy delivered as a single intratumoral infusion to treat pediatric patients with recurrent high-grade glioma, an indication with no FDA-approved therapies.

Ownership category

akta.pro rank

Product category

Oncolytic Virus Immunotherapy

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• Oncolytic virus therapy
• Pediatric brain tumors
• Immunotherapy biotech
• HSV-based therapeutics
• Clinical-stage biopharmaceuticals

Headquarters

HQ city

Bala Cynwyd

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Pharmaceutical/Biotech Revenue (Future): Treovir is a pre-revenue clinical-stage company. If G207 receives FDA and EMA approval, revenue would be generated through commercial sales of the therapy for pediatric brain tumors. No specific pricing, reimbursement, or commercial launch timeline has been disclosed.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Core offering

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 (herpes simplex virus type 1) immunotherapy engineered to selectively infect and kill tumor cells while leaving healthy cells unharmed. G207 is administered as a single infusion directly into the brain tumor, causing direct tumor cell death and recruiting the patient's own immune system (T-cell response) to fight the cancer. The company is pursuing FDA approval of G207 for pediatric high-grade glioma, an indication with no currently approved therapies.

Product overview

Treovir is a clinical-stage biopharmaceutical company developing G207, a modified oncolytic HSV-1 immunotherapy for pediatric brain tumors. The core product G207 is a targeted oncolytic virus therapy administered as a single infusion directly into the tumor. The company has completed Phase 1 studies demonstrating safety and improved survival, and launched a Phase 2 study in 2024 to support FDA registration. If successful, G207 would become the first-ever approved therapy for pediatric glioma.

Differentiator

Problem solved

Functional benefit

Products and services

• G207 Oncolytic Immunotherapy G207 is a modified oncolytic HSV-1 immunotherapy that selectively infects and kills tumor cells while sparing healthy cells. Administered as a single direct intratumoral infusion, it triggers tumor cell death and recruits T-cell immune responses to convert immunologically 'cold' tumors 'hot'. It is being developed for pediatric brain tumors including recurrent high-grade glioma and medulloblastoma, targeting an indication with no currently approved FDA therapies.
• Phase 2 Pediatric Glioma Clinical Trial (NCT04482933) Active Phase 2 clinical trial of G207 in children with recurrent high-grade glioma, designed to support FDA market approval. Currently enrolling at MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center.
• Phase 1 Pediatric HGG Clinical Trial (NCT02457845) Completed Phase 1 clinical study of G207 in 12 pediatric patients with recurrent high-grade glioma, demonstrating improved overall survival versus historical controls with no serious adverse events. Results published in the New England Journal of Medicine (Friedman GK, April 2021).
• Phase 1 Cerebellar Tumor Clinical Trial (NCT03911388) Phase 1 study of G207 in combination with 5Gy radiation in patients with recurrent medulloblastoma and other cerebellar tumors. Enrolling up to 15 patients at MD Anderson Cancer Center, Children's of Alabama, and St. Louis Children's Hospital.

Quantifiable outcome

• Overall survival improved to 12.2 months vs 5.6 months historical control in Phase 1 pediatric study
• +2 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core.

• MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson Cancer Center is an enrolling site for both the Phase 2 clinical trial of G207 in children with recurrent high-grade glioma and the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors. MD Anderson is one of the world's most respected cancer treatment centers.
• Memorial Sloan Kettering Cancer CentercoreStrategic or Co-development PartnerMemorial Sloan Kettering Cancer Center is an enrolling site for the Phase 2 clinical trial of G207 in children with recurrent high-grade glioma. Memorial Sloan Kettering is a leading pediatric oncology center.
• Children's of AlabamacoreStrategic or Co-development PartnerChildren's of Alabama is an enrolling site for the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors. The hospital has been involved in pediatric brain tumor research with G207.
• St. Louis Children's HospitalcoreStrategic or Co-development PartnerSt. Louis Children's Hospital is an enrolling site for the Phase 1 study of G207 in combination with radiation for recurrent medulloblastoma and cerebellar tumors.
• Pediatric Brain Tumor Consortium (PBTC)coreStrategic or Co-development PartnerPBTC is a collaborative research consortium focused on developing new treatments for pediatric brain tumors. The logo appears on Treovir's website indicating partnership in pediatric brain tumor clinical research.
• National Institutes of Health (NIH)coreStrategic or Co-development PartnerNIH supports pediatric brain tumor research and is listed as a partner on Treovir's website. The NIH logo appears indicating research funding or collaborative support for G207 development.
• UAB MedicinecoreStrategic or Co-development PartnerUAB (University of Alabama at Birmingham) Medicine is a key research partner. Co-directed the Neuro Oncology Program and Brain Tumor SPORE in the UAB O'Neal Comprehensive Cancer Center. Founder Yancey Gillespie is Professor Emeritus of Neurosurgery at UAB.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Replimune: Replimune is a clinical-stage biotech developing a proprietary platform of engineered oncolytic viruses (RP1, RP2, RP3) across multiple solid tumor indications. It is a direct modality peer with greater pipeline breadth and public-market funding that competes for the same oncolytic virus partnering and clinical site capacity.
• SillaJen: SillaJen developed Pexa-Vec (JX-594), an oncolytic vaccinia virus, in hepatocellular carcinoma and other solid tumors. It is a clinical-stage direct peer in the oncolytic virus modality with overlapping clinical-trial and regulatory dynamics.
• Oncorus: Oncorus developed intratumorally and intravenously administered oncolytic HSV-1 immunotherapies for cancer. It is a direct peer in the oncolytic HSV modality that Treovir is built on, with overlapping mechanistic and manufacturing considerations.
• Genelux: Genelux is developing Olvi-Vec, an oncolytic vaccinia virus, in solid tumors including lung and ovarian cancers. It is a direct modality peer in the clinical-stage oncolytic virus space, competing for investigator attention and partnership capital.
• Vyriad: Vyriad is developing engineered oncolytic vesicular stomatitis virus (VSV) and measles virus platforms for solid tumors. It is a direct peer in clinical-stage oncolytic virus development with similar regulatory and manufacturing challenges to Treovir.
• DNAtrix: DNAtrix is a clinical-stage oncolytic virus company developing DNX-2401 (tasadenoturev), an oncolytic adenovirus for brain tumors including glioblastoma. It is the most directly comparable peer because it targets the same brain tumor indication with the same oncolytic virus modality as Treovir.
• Candel Therapeutics: Candel Therapeutics (formerly Advantagene) develops CAN-2409, an oncolytic adenovirus gene therapy, with programs in prostate cancer and high-grade glioma. It directly overlaps Treovir in intratumoral oncolytic virus delivery and brain-tumor indication.

Emerging players

• Day One Biopharmaceuticals: Day One Biopharmaceuticals is a commercial-stage pediatric oncology company (tovorafenib/Day101) focused exclusively on childhood cancers. It is a peer in the pediatric oncology commercial and clinical-development niche that G207 would enter upon approval.
• Y-mAbs Therapeutics: Y-mAbs Therapeutics develops and commercializes antibody-based oncology therapies targeted at pediatric tumors, including Danyelza for neuroblastoma. It is comparable as a small, pediatric-cancer-focused biotech operating in the same regulatory and reimbursement environment.

Broad incumbents

• Amgen (Imlygic / T-Vec): Amgen developed and commercializes Imlygic (talimogene laherparepvec), the first FDA-approved oncolytic virus therapy, for melanoma. As the established commercial oncolytic virus player, it defines the regulatory and commercial template Treovir would face in bringing G207 to market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Treovir